338 related articles for article (PubMed ID: 33594731)
1. Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis.
Marcant P; Balayé P; Merhi R; Jendoubi F; Nosbaum A; Raison-Peyron N; Du-Thanh A; Lasek A; Ferrier le Bouedec MC; Tetart F; Valois A; Barbarot S; Soria A; Jachiet M; Staumont-Sallé D;
J Eur Acad Dermatol Venereol; 2021 Jun; 35(6):e394-e396. PubMed ID: 33594731
[No Abstract] [Full Text] [Related]
2. Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient.
Zhang S; Lu L; Feng J; Hu Z; Song H; Yang L; Liu Y; Chen D; Wang T
J Dermatolog Treat; 2023 Dec; 34(1):2229466. PubMed ID: 37369546
[TBL] [Abstract][Full Text] [Related]
3. Safety of dupilumab in a 5-month-old infant with severe atopic dermatitis.
Havele SA; Khurana MC; McMahon P; Murthy AS; Perman MJ; Treat JR
Pediatr Dermatol; 2022 Mar; 39(2):291-294. PubMed ID: 35434859
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab ocular surface disease occurs predominantly in patients receiving dupilumab for atopic dermatitis: A multi-institution retrospective chart review.
Waldman RA; DeWane ME; Sloan SB; King B; Grant-Kels JM
J Am Acad Dermatol; 2021 Sep; 85(3):735-736. PubMed ID: 31325553
[No Abstract] [Full Text] [Related]
5. New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab.
Bortoluzzi P; Ferrucci S; Galimberti D; Garavelli F; Pozzo Giuffrida F; Pizzati A; Marzano AV; Mapelli C
Br J Dermatol; 2022 Jan; 186(1):186-187. PubMed ID: 34431510
[TBL] [Abstract][Full Text] [Related]
6. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
[TBL] [Abstract][Full Text] [Related]
8. Eczema herpeticum and herpetic keratitis after the loading dose of dupilumab in a worsening atopic dermatitis: causality?
Benaglia C; Aromolo IF; Giacalone S; Morini N; Zussino M; Di Benedetto A; Marzano AV; Ferrucci SM
Int J Dermatol; 2023 Dec; 62(12):1547-1548. PubMed ID: 37715466
[No Abstract] [Full Text] [Related]
9. Severe atopic dermatitis: Dupilumab is not just safer, but more efficient.
Giavina-Bianchi M; Rizzo LV; Giavina-Bianchi P
Allergol Immunopathol (Madr); 2020; 48(6):792-797. PubMed ID: 32249095
[TBL] [Abstract][Full Text] [Related]
10. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
[TBL] [Abstract][Full Text] [Related]
11. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
Fargnoli MC; Esposito M; Ferrucci S; Girolomoni G; Offidani A; Patrizi A; Peris K; Costanzo A; Malara G; Pellacani G; Romanelli M; Amerio P; Cristaudo A; Flori ML; Motolese A; Betto P; Patruno C; Pigatto P; Peccianti C; Stinco G; Zalaudek I; Bianchi L; Boccaletti V; Cannavo SP; Cusano F; Lembo S; Mozzillo R; Gallo R; Potenza C; Rongioletti F; Tiberio R; Grieco T; Micali G; Persechino S; Pettinato M; Pucci S; Stingeni L; Caruso C; Argenziano G;
J Dermatolog Treat; 2022 Mar; 33(2):1146-1149. PubMed ID: 32436765
[No Abstract] [Full Text] [Related]
12. Rapid resolution of diffuse warts following initiation of dupilumab for severe atopic dermatitis.
Netravali IA; Sockler PG; Heimall J; Treat JR
Pediatr Dermatol; 2024; 41(2):275-278. PubMed ID: 37680146
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Thaçi D; Deleuran M; Blauvelt A; Bissonnette R; de Bruin-Weller M; Hide M; Sher L; Hussain I; Chen Z; Khokhar FA; Beazley B; Ruddy M; Patel N; Graham NMH; Ardeleanu M; Shumel B
Am J Clin Dermatol; 2020 Aug; 21(4):567-577. PubMed ID: 32557382
[TBL] [Abstract][Full Text] [Related]
14. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
[TBL] [Abstract][Full Text] [Related]
15. Severe eczema in Wiskott-Aldrich syndrome-related disorder successfully treated with dupilumab.
Alzahrani F; Miller HK; Sacco K; Dupuy E
Pediatr Dermatol; 2024; 41(1):143-144. PubMed ID: 37469225
[TBL] [Abstract][Full Text] [Related]
16. A critical appraisal and implications of the new National Institute for Health and Care Excellence guideline on dupilumab for treating moderate-to-severe atopic eczema.
Weidinger S; Apfelbacher C
Br J Dermatol; 2019 Mar; 180(3):435-437. PubMed ID: 30821391
[No Abstract] [Full Text] [Related]
17. Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients.
Achten R; Thijs J; van Luijk C; Knol E; Delemarre E; de Graaf M; Bakker D; de Boer J; van Wijk F; de Bruin-Weller M
Clin Exp Allergy; 2023 Feb; 53(2):239-243. PubMed ID: 36550628
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab for atopic dermatitis.
Pediatr Dermatol; 2021 Nov; 38(6):1559-1560. PubMed ID: 34931365
[No Abstract] [Full Text] [Related]
20. Safety of dupilumab in patients with atopic dermatitis: expert opinion.
Francuzik W; Alexiou A; Worm M
Expert Opin Drug Saf; 2021 Sep; 20(9):997-1004. PubMed ID: 34114910
[No Abstract] [Full Text] [Related]
[Next] [New Search]
